$SAVA - CASSAVA SCIENCES TOPLINE PHASE 3 DATA DID NOT MEET CO-PRIMARY ENDPOINTS
CASSAVA SCIENCES INC: SIMUFILAM CONTINUED TO DEMONSTRATE AN OVERALL FAVORABLE SAFETY PROFILE
CASSAVA SCIENCES INC: SIMUFILAM DID NOT SHOW A SIGNIFICANT REDUCTION IN COGNITIVE OR FUNCTIONAL DECLINE VERSUS PLACEBO
From X
Disclaimer: The above content reflects only the author's opinion and does not represent any stance of CoinNX, nor does it constitute any investment advice related to CoinNX.